Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to recent findings from the HARMONi-2 trial. “This…